Kinavet CA-1 drew FDA ire last month for bogus marketing claims, but the canine cancer drug, intended to treat mast cell tumors, has gone ahead to a Phase III clinical trial in Florida.
Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's Enbrel in a head-to-head study.
With media organizations broadcasting lurid images of the Liberian military's violent effort to enforce a quarantine in an effort to corral Ebola in the slums in Monrovia, the frenzy of attention continued to concentrate a spotlight on the sudden rush to get early-stage experimental treatments or vaccines to West Africa.
Amid a sea of companies creating mobile medical devices, a Philadelphia startup hopes to set itself apart and deliver an innovative product that provides quick, at-home lab diagnostics on a smartphone.
AstraZeneca's antibiotic combination treatment beat out standard meropenem in treating complicated infections, the company said, setting the table for a near-term shot at regulatory approval.
Researchers at the Institute of General Physics at the Russian Academy of Sciences and the Moscow Institute of Physics and Technology said their advancement in biocomputing using nanoparticles is a step towards creating drug-delivering nanorobots.
Researchers successfully delivered the immunosuppressant tacrolimus in a self-assembled hydrogel, enabling localized therapy in patients receiving a tissue graft transplant of the leg, hand or face.
Boston Scientific has just announced plans to launch new fractional flow reserve and atherectomy guidewires in 2015 in collaboration with Japanese medical component specialist Asahi Intecc.
Columbia University scientists showed that it is possible to control the size of the blood-brain barrier opening by varying the pressure of an ultrasound beam, a discovery that could herald major breakthroughs in the treatment of neurological diseases.
Back in January, the prestigious Sanford-Burnham Medical Research Institute amended its ethos, promising to more closely marry its work to therapeutic development and become a partner of choice for drugmakers. Now, the 38-year-old organization has chosen the leader to get it there, convincing GlaxoSmithKline's Perry Nisen to take the reins as its new CEO.